Spatial omics market seen reaching $540 million by 2030

The Business Research Company says the spatial omics market will grow from $330 million in 2025 to $540 million by 2030, powered by demand in drug discovery, precision medicine and disease biology research. North America held the largest share in 2025, while Asia-Pacific is expected to grow fastest.

Why it matters: - Spatial omics is becoming a key tool for life sciences because it links molecular data with tissue location. - The market’s growth signals stronger demand for technologies that support disease research, biomarker discovery and drug development. - The category could benefit from rising genetic disease burden and broader use in precision medicine.

What happened: - The Business Research Company published a spatial omics market report on Aug. 30, 2026. - The report says the market will rise from $0.33 billion in 2025 to $0.37 billion in 2026. - The report projects the market will reach $0.54 billion by 2030. - The report puts the market on an 11.3% CAGR in the historical period and a 10.0% CAGR through 2030.

The details: - Spatial omics combines spatial analysis with omics technologies to study biomolecules in their tissue context. - The report ties historical growth to more genomics research funding, expansion of academic life sciences programs, better molecular imaging tools, wider omics consumables availability and more disease biology research. - Future growth is expected from greater adoption in drug discovery, more precision medicine investment, AI-driven biological data analysis, higher demand for spatially resolved biomarkers and more pharmaceutical R&D spending. - The report points to expanded use of spatial transcriptomics, multi-omics integration, high-resolution imaging systems, advanced data visualization tools and tissue-level molecular mapping. - North America held the largest market share in 2025. - Asia-Pacific is expected to be the fastest-growing region during the forecast period. - The report also covers South East Asia, Western Europe, Eastern Europe, South America, the Middle East and Africa. - A free sample of the report is available here. - The full report is available here.

Between the lines: - Rising hereditary disease cases are adding urgency to tools that can map molecular changes inside tissues. - The report cites Australian National Blood Authority data showing hereditary haemophilia A patients increased from 2,681 in 2022–2023 to 2,788 in 2023–2024. - That kind of disease burden supports broader spending on spatial omics platforms and downstream analysis software.

What's next: - The market is likely to see more adoption in research workflows that combine imaging, genomics and AI analysis. - Vendors may compete more on resolution, data visualization and multi-omics integration. - Growth could accelerate as pharmaceutical companies expand R&D and precision medicine programs. - The report’s 2026 edition adds market attractiveness scoring, TAM analysis, company scoring matrices, Excel forecasting dashboards, market hotspot infographics and updated graphics and tables.

The bottom line: - Spatial omics is moving from a niche research tool toward a broader life sciences market with clear clinical and commercial momentum.